Survodutide – Next-Generation Dual-Agonist Peptide

Survodutide is an innovative dual-agonist peptide designed to target both GLP-1 (Glucagon-Like Peptide-1) and Glucagon receptors, representing a new direction in metabolic and weight-management research. By activating complementary metabolic pathways, Survodutide is being studied for its potential role in energy balance, fat metabolism, and glycemic regulation. 

Survodutide combines:

• GLP-1 receptor agonism, associated with appetite regulation and glucose control
   
• Glucagon receptor agonism, linked to increased energy expenditure and fat oxidation
   

This dual-pathway approach aims to enhance metabolic efficiency while supporting sustained research outcomes.

• Dual GLP-1 / Glucagon receptor agonist
   
• High-purity peptide for research use
   
• Designed for advanced metabolic research applications
   
• Lyophilized powder or pre-filled pen formats available (customizable)
   
• Batch-specific COA provided for every order

Survodutide is widely utilized in preclinical and laboratory research focused on:

• Metabolic disorders
   
• Weight management mechanisms
   
• Energy expenditure and lipid metabolism
   
• Next-generation peptide therapeutics

Manufactured under strict quality control standards, Survodutide from ShiLai™Healthcare is produced using validated peptide synthesis processes to ensure:

• High purity and stability
   
• Batch-to-batch consistency
   
• Secure and reliable global supply

ShiLai™Healthcare supports partners with:

• Custom concentrations and packaging
   
• Private labeling and OEM services
   
• Stable international logistics with guaranteed delivery options
   

For research use only. Not for human or veterinary use